Human Antibodies - Volume Pre-press, issue Pre-press

Authors: Abed, Hayder H. | Al-Ziaydi, Ahmed Ghdhban | Taher, Ihab Abbas | Al Dulaimi, Ahmed K.

Article Type: Research Article

Abstract: BACKGROUND: COVID-19 is a highly contagious virus that is rapidly spreading across the world. As the number of COVID-19 patients is quickly rising, and certain nations and areas, such as the third world countries, lack the medical resources, it is critical to track and monitor a patient’s status using blood parameters on regular testing. The aim of this study is to compare the serum D-dimer levels, Ferritin, CRP, WBCs, Lymphocytes, and Neutrophils in male and female patients infected with COVID-19. OBJECTIVE AND METHODS: The study procedure includes evaluating the D-dimer level, Ferritin, CRP, WBCs, lymphocytes, and …neutrophils in 116 patients infected with COVID-19 (48 Females and 68 Males). RESULT: The result of this study shows a significant increase in the D-dimer level in males 1618 ± 247.7 ng/ml compared to females 684.5 ± 53.69 ng/ml and a significant increase in Ferritin level in males 525.6 ± 69.55 μ g/L compared to females 254.1 ± 33.73 μ g/L. However, no other significant change is seen in the other parameters (CRP, LDH, and WBCs, L, and N) although all of these parameters are abnormal, compared to the normal reference values. CONCLUSION: This study concludes that there is a significant increase in the D-dimer and Ferritin concentrations in male patients compared to female patients, who were infected with COVID-19. Also there are no significant differences in other parameters (CRP, LDH, WBCs, L, and N) between male and female patients. Show more

Keywords: COVID-19, haematological parameters, D-dimer, ferritin

DOI: 10.3233/HAB-220006

Citation: Human Antibodies, vol. Pre-press, no. Pre-press, pp. 1-5, 2022

Authors: Pourmontaseri, Hossein | Habibzadeh, Niloofar | Entezari, Sarina | Samadian, Fatemeh | Kiyani, Shamim | Taheri, Mina | Ahmadi, Ali | Fallahi, Mohammad Sadegh | Sheikhzadeh, Farzad | Ansari, Arina | Tamimi, Amirhossein | Deravi, Niloofar

Article Type: Research Article

Abstract: BACKGROUND: Acute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL. METHODS: We gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and …PubMed for English language publications up to 2020. RESULTS: The most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects. CONCLUSION: Appling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field. Show more

Keywords: Monoclonal antibodies, acute lymphocytic leukemia, anti-cancer, targeted therapy

DOI: 10.3233/HAB-211511

Citation: Human Antibodies, vol. Pre-press, no. Pre-press, pp. 1-14, 2022